Comparison between efficacy and safety of rituximab plus CHOP regimen and CHOP regimen for treatment of newly diagnosed patients with diffuse large B-cell lymphoma.
- Author:
Wei XU
1
;
Jian-Yong LI
;
Zhi-Hong ZHANG
;
Hong-Xia QIU
;
Si-Xuan QIAN
;
Han-Xin WU
;
Hua LU
;
Rui-Lan SHENG
Author Information
1. Department of Hematology, The First Hospital of Nanjing Medical University, Jiangsu Province People Hospital, Nanjing 210029, Jiangsu Province, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Antibodies, Monoclonal;
administration & dosage;
adverse effects;
Antibodies, Monoclonal, Murine-Derived;
Antineoplastic Combined Chemotherapy Protocols;
adverse effects;
therapeutic use;
Cyclophosphamide;
adverse effects;
therapeutic use;
Doxorubicin;
adverse effects;
therapeutic use;
Female;
Humans;
Lymphoma, Large B-Cell, Diffuse;
drug therapy;
Male;
Middle Aged;
Prednisone;
adverse effects;
therapeutic use;
Prospective Studies;
Rituximab;
Safety;
Vincristine;
adverse effects;
therapeutic use;
Young Adult
- From:
Journal of Experimental Hematology
2008;16(4):933-937
- CountryChina
- Language:Chinese
-
Abstract:
The aim of this study was to compare the efficacy of rituximab plus CHOP regimen and CHOP regimen on newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL), and analyze their toxicities. A total of 69 patients were enrolled from July 2003 to Dec 2006. The patients were non-randomly were divided into 2 groups: 36 received CHOP alone (CHOP group) and 33 received rituximab plus CHOP (R-CHOP group). The complete response (CR) rates, overall survival (OS) and side events of the 2 groups were compared. The results showed that the CR rate in R-CHOP group was higher than that in CHOP group (69.7% vs 47.2%, p = 0.049); especially in patients of male, Ann Arbor III - IV and IPI 3 - 5 (p = 0.017, p = 0.005 and p = 0.000). The estimated mean OS in R-CHOP group was longer than that in CHOP group (45.7 months vs 35.2 months, p = 0.145), and also in the estimated mean progression free survival (PFS) (38.5 months vs. 24.6 months, p = 0.017). The major adverse events in combination group were infusion-related responses which could be well tolerated in patients, and hematological toxicities which were similar to those in CHOP group. In conclusions, Rituximab increases the therapeutic efficacy of CHOP regimen on newly diagnosed patients with DLBCL, without a clinically significant increase in toxicity.
